BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director Orbimed Advisors Llc acquired 625,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
BlossomHill Therapeutics Price Performance
BLSM stock traded down $0.28 during trading on Wednesday, reaching $16.24. 424,181 shares of the company were exchanged, compared to its average volume of 390,293. BlossomHill Therapeutics, Inc. has a 52-week low of $15.25 and a 52-week high of $17.25.
Featured Articles
- Five stocks we like better than BlossomHill Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
